Because of the ability of pioglitazone to interfere with ET-1 system as well as to increase peripheral insulin sensitivity, this compound might be a promising therapeutic option in patients with resistant hypertension and in those with hypertension concomitant with insulin resistance. The gene discussed is EDN1; the disease is Insulin resistance.